KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Land & Improvements (2016)

Historic Land & Improvements for Jazz Pharmaceuticals (JAZZ) over the last 3 years, with Q1 2016 value amounting to $1.8 million.

  • Jazz Pharmaceuticals' Land & Improvements rose 3318.84% to $1.8 million in Q1 2016 from the same period last year, while for Mar 2016 it was $1.8 million, marking a year-over-year increase of 3318.84%. This contributed to the annual value of $1.8 million for FY2015, which is 1473.82% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Land & Improvements stood at $1.8 million for Q1 2016, which was up 3318.84% from $1.8 million recorded in Q4 2015.
  • In the past 5 years, Jazz Pharmaceuticals' Land & Improvements ranged from a high of $1.8 million in Q1 2016 and a low of $1.4 million during Q1 2015
  • Its 3-year average for Land & Improvements is $1.7 million, with a median of $1.7 million in 2014.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Land & Improvements crashed by 1775.92% in 2015, and later soared by 3318.84% in 2016.
  • Jazz Pharmaceuticals' Land & Improvements (Quarter) stood at $1.5 million in 2014, then grew by 14.74% to $1.8 million in 2015, then rose by 3.55% to $1.8 million in 2016.
  • Its Land & Improvements stands at $1.8 million for Q1 2016, versus $1.8 million for Q4 2015 and $1.8 million for Q3 2015.